KlufasMARegilloCDMandavaNKMillerEG.Evolution of antivascular endothelial growth factor clinical trial design for treating neovascular age-related macular degeneration. J Vitreoretin Dis. 2026;10(4):582-592.
2.
RoweLWMachaNNAggarwalNSinghRPMaturiRK.Visual acuity and durability outcomes of faricimab compared with other antivascular endothelial growth factor agents within routine clinical practice for neovascular age-related macular degeneration. J Vitreoretin Dis. 2026;10(4):593-601.
3.
MachaNNRoweLWAggarwalNSinghRPMaturiRK.Visual acuity and durability outcomes of faricimab compared with other antivascular endothelial growth factor agents within routine clinical practice for diabetic macular edema. J Vitreoretin Dis. 2026;10(4):602-610.
4.
ChenMYKamalSMDasanR, et al. Association of the social deprivation index with the severity and treatment of diabetic retinopathy. J Vitreoretin Dis. 2026;10(4):611-621.
5.
TranTGohJRogersSQureshiSLimLL.Biomarkers of diabetic macular edema on optical coherence tomography after cataract surgery. J Vitreoretin Dis. 2026;10(4):622-631.
6.
BineshfarNGhaneNBerrocalAM.Early Signs of microvascular impairment on optical coherence tomography angiography in pediatric patients with type 1 diabetes without clinical retinopathy. J Vitreoretin Dis. 2026;10(4):632-639.
7.
MilnerDPatnaikJLAuerE, et al. The clinical association of maternal asthma and the development of retinopathy of prematurity in preterm infants. J Vitreoretin Dis. 2026;10(4):640-646.
8.
FujimotoSKokameGTMaenoTUsuiSMaruyamaKNishidaK.No Optic Pit Retinoschisis: a risk factor for glaucoma. J Vitreoretin Dis. 2026;10(4):647-654.
9.
AuerEAGnanarajRLynchAM, et al. Menopausal hormone therapy and conversion from intermediate to advanced age-related macular degeneration. J Vitreoretin Dis. 2026;10(4):655-663.
10.
ZhaoCSDoDVSanisloSR, et al. Prevalence of systemic comorbidities and ocular complications in patients with bilateral retinal telangiectasia. J Vitreoretin Dis. 2026;10(4):664-671.
11.
D’CunhaRHemesathAZhengY, et al. Effect of intravitreal anti-VEGF injections on the vitreomacular interface in treatment-naïve eyes with central retinal vein occlusion. J Vitreoretin Dis. 2026;10(4):672-678.
12.
AlmeidaDRPChinEKMahajanVB. Preoperative classification of submembrane spaces for optical coherence tomography–guided epiretinal membranectomy. J Vitreoretin Dis. 2026;10(4): 679-688.
13.
AbrahamJRArlineABalaS, et al. Quality improvement in vitreoretinal surgery. J Vitreoretin Dis. 2026;10(4):689-693.
14.
TranTMDuongRTOleyMACusickM.Demographic variations in presentation, treatment, and outcomes in patients with rhegmatogenous retinal detachments. J Vitreoretin Dis. 2026; 10(4):694-704.
15.
MeshkinRSHoffmanSEChaayaC, et al. Time-driven, activity-based cost analysis of secondary intraocular lens implantation. J Vitreoretin Dis. 2026;10(4):705-711.
16.
ParoliniBApuzzoASpinelliABesozziG.Patching peripheral retinal breaks on atrophic choroid: a prospective pilot study to prevent redetachment. J Vitreoretin Dis. 2026;10(4):712-716.
17.
MishraAVDeonarainDMLohGKTennantMTS. Outcomes of treatment for central serous chorioretinopathy with half-fluence, half-dose photodynamic therapy. J Vitreoretin Dis. 2026;10(4):717-721.
18.
SerhanHAAshrafSSaeedH, et al. Efficacy and safety of carbonic anhydrase inhibitors in the management of central serous chorioretinopathy. J Vitreoretin Dis. 2026;10(4):722-731.
19.
AmiriIJiaoCZhangAY. Multimodal diagnostic accuracy of GPT-4.o, Claude 3.7, and Gemini 2.5 on real-world retina cases. J Vitreoretin Dis. 2026;10(4):732-739.
20.
CohenSAPrasadPSSridharJ.An Altmetric and bibliometric comparative analysis from 2014 to 2023 of the 100 most-mentioned and 100 most-cited articles about diabetic retinopathy. J Vitreoretin Dis. 2026;10(4):740-750.
21.
WibbelsmanTDCalottiMCalottiR, et al. Readability of retina patient education materials generated with a large language model. J Vitreoretin Dis. 2026;10(4):751-758.
22.
RiottoEBatisVToblerEStapplerTWolfensbergerTKonstantinidisL.Macular hole closure with autologous internal limiting membrane plug and heavy silicone oil tamponade within 24 hours after vitrectomy. J Vitreoretin Dis. 2026;10(4):759-763.
23.
LoyaAChenVSiddiquiTRaoPChangEY.Morphologic changes of macular choroidal neovascularization on OCT angiography following faricimab therapy in patients with AMD. J Vitreoretin Dis. 2026;10(4):764-769.
24.
HandePMishraSTendulkarKPrabhuVRizviSVenkateshR.Multimodal imaging in acute idiopathic maculopathy: insights from retro-mode scanning laser ophthalmoscopy. J Vitreoretin Dis. 2026;10(4):770-775.
25.
KumarasamyCManayathGJNinanRVergheseS.Venous overload choroidopathy with coexisting chronic central serous chorioretinopathy and uveal effusion syndrome. J Vitreoretin Dis. 2026;10(4):776-784.
26.
ShakeelASreenivasanJAppakudalAR.Efficacy of intravitreal caspofungin in a case of bilateral Candida albicans endophthalmitis. J Vitreoretin Dis. 2026;10(4):785-788.
ChungMEWaiKM.Recurrent macular edema associated with belzutifan therapy for metastatic renal cell carcinoma. J Vitreoretin Dis. 2026;10(4):792-796.
29.
TranJHHosseiniHTsuiEAuA.VKH-like syndrome in a patient on tofacitinib. J Vitreoretin Dis. 2026;10(4):797-801.
30.
AndersonHESoodSGolshaniC.Acute unilateral vision loss following recombinant zoster (Shingrix) vaccination: a case of presumptive Purtscher-like retinopathy. J Vitreoretin Dis. 2026; 10(4):802-807.
31.
KhanHMSumitaFAGPretiRCSarrafDNavajasEV.CNGA3-related achromatopsia: a 10-year follow-up. J Vitreoretin Dis. 2026;10(4):808-813.
32.
Arias-GonzálezNBalikovDACiccioliM, et al. A newborn with Down–Klinefelter syndrome and bilateral congenital cataracts harboring a novel MAPKAPK3 mutation. J Vitreoretin Dis. 2026;10(4):814-818.
